Clinitech Laboratory Ltd
Founded in 1990, Clinitech Laboratory Limited provides diagnostic and health testing and services.[1]
- Market Cap ₹ 7.85 Cr.
- Current Price ₹ 34.4
- High / Low ₹ 121 / 34.4
- Stock P/E 20.1
- Book Value ₹ 38.7
- Dividend Yield 0.00 %
- ROCE 9.21 %
- ROE 6.30 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.89 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.1% over last 3 years.
- Debtor days have increased from 43.6 to 68.3 days.
- Working capital days have increased from 60.8 days to 115 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
4.55 | 6.38 | 6.35 | 6.40 | 8.23 | |
3.72 | 5.31 | 4.99 | 5.41 | 7.40 | |
Operating Profit | 0.83 | 1.07 | 1.36 | 0.99 | 0.83 |
OPM % | 18.24% | 16.77% | 21.42% | 15.47% | 10.09% |
0.04 | 0.07 | 0.02 | 0.04 | 0.23 | |
Interest | 0.08 | 0.06 | 0.07 | 0.09 | 0.06 |
Depreciation | 0.25 | 0.38 | 0.45 | 0.44 | 0.45 |
Profit before tax | 0.54 | 0.70 | 0.86 | 0.50 | 0.55 |
Tax % | 25.93% | 27.14% | 29.07% | 26.00% | 29.09% |
0.40 | 0.51 | 0.61 | 0.37 | 0.39 | |
EPS in Rs | 6.00 | 3.40 | 4.07 | 2.20 | 1.71 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
TTM: | 29% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -9% |
TTM: | 8% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 0.67 | 1.50 | 1.50 | 1.68 | 2.28 |
Reserves | 0.72 | 0.35 | 0.88 | 1.87 | 6.55 |
0.54 | 0.89 | 1.03 | 0.87 | 0.00 | |
0.80 | 0.94 | 2.62 | 1.19 | 1.88 | |
Total Liabilities | 2.73 | 3.68 | 6.03 | 5.61 | 10.71 |
0.84 | 1.65 | 1.33 | 1.71 | 3.13 | |
CWIP | 0.08 | 0.41 | 0.56 | 0.94 | 0.00 |
Investments | 0.09 | 0.14 | 2.02 | 0.07 | 0.07 |
1.72 | 1.48 | 2.12 | 2.89 | 7.51 | |
Total Assets | 2.73 | 3.68 | 6.03 | 5.61 | 10.71 |
Cash Flows
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
0.38 | 0.96 | 1.25 | 0.11 | -0.88 | |
0.54 | -1.47 | -0.65 | -0.64 | -0.73 | |
-0.88 | 0.29 | 0.09 | 0.45 | 3.98 | |
Net Cash Flow | 0.04 | -0.22 | 0.68 | -0.08 | 2.37 |
Ratios
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 44.92 | 20.60 | 28.17 | 34.22 | 68.30 |
Inventory Days | 32.21 | 40.28 | 43.68 | 92.91 | 124.01 |
Days Payable | 164.61 | 130.90 | 124.79 | 116.14 | 147.40 |
Cash Conversion Cycle | -87.48 | -70.03 | -52.95 | 10.99 | 44.90 |
Working Capital Days | 48.13 | 25.74 | 9.77 | 57.60 | 114.87 |
ROCE % | 32.55% | 30.24% | 14.81% | 9.21% |
Documents
Announcements
-
Appointment of Company Secretary and Compliance Officer
6 Jun - Company Secretary resigned; new appointment made; INR 20 lakh term loan approved on June 6, 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E June 06, 2025 At 11.30 AM At Its Registered Office
6 Jun - Company Secretary changed; INR 20 lakh term loan approved on June 6, 2025.
-
Board Meeting Intimation for 02Nd Board Meeting Of The Company For FY 2025-26 At Its Registered Office
3 Jun - Board meeting on June 6 to note resignation and appoint new Company Secretary & Compliance Officer.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
2 Jun - Company Secretary & Compliance Officer resigned effective 2 June 2025 for better prospects.
-
Financial Results For 31.03.2025
23 May - Approved audited financial results for FY ended March 31, 2025 with unmodified audit opinion.
Annual reports
No data available.
Business Profile[1] The company performs over 150 tests in its centers, categorized into Biochemical Tests, Immunology Tests, Hematology Tests, Molecular Biology Tests, Serology Tests, Microbiology Tests, and Histopathology Tests.